Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AlphaNorth increases its position in AGN.c
View:
Post by StockHawk1 on Aug 31, 2022 6:08pm

AlphaNorth increases its position in AGN.c

Algernon Pharmaceuticals (AGN.c AGNPF) announced last week that its largest shareholder, AlphaNorth Asset Management has increased its ownership position in AGN
 
AlphaNorth acquired 150,000 shares in AGN's recent PP financing. 
 
With this AlphaNorth has an equity interest in AGN of over 13%.
 
This increased position is a big vote of confidence from AlphaNorth, for both AGN's drug pipeline and mgmt. Overall AGN is up 57% in the last month.
 
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-largest-shareholder-alphanorth-111500507.html
 
Today, AGN closed in the green again @ $5.39
MC $10.694M
 
Be the first to comment on this post
Algernon Pharmaceuticals Inc.